Achiko

Achiko Achiko AG (SIX: ACHI.SW; www.achiko.com) is developing disruptive diagnostic solutions that put people first.

Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com) is developing disruptive diagnostic solutions that put people first. The Company’s lead product, ApatameX™, is a rapid, reliable Covid-19 test with a companion app, Teman Sehat™, offering a user-friendly digital health passport. AptameX™ and Teman Sehat™ were launched in Indonesia in mid-2021 and AptameX™ received the CE Mark in the European Union in May 2022. The AptameX™ DNA aptamer tests can be rapidly chemically synthesised, are cost-effective, easily scalable and have broad potential across multiple disease areas. Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of diseases in the rapidly evolving healthcare diagnostics field. Headquartered in Zurich, Achiko has offices in Jakarta, and staff around the world.

Achiko AG Company Update
19/04/2023

Achiko AG Company Update

Achiko seeks to improve the lives of its customers through the use of innovative application technology.

https://www.nature.com/articles/s41579-022-00846-2
14/01/2023

https://www.nature.com/articles/s41579-022-00846-2

Long COVID is an often debilitating illness of severe symptoms that can develop during or following COVID-19. In this Review, Davis, McCorkell, Vogel and Topol explore our knowledge of long COVID and highlight key findings, including potential mechanisms, the overlap with other conditions and potent...

13/01/2023

COVID-19 may no longer be a pandemic, but the disease likely reduced the availability of the US workforce by as much as 2.6 percent in 2022—a burden on productivity that could last for years.

As Achiko is proceeding to sales and is currently going through external validation, we are proud to report that early r...
21/12/2022

As Achiko is proceeding to sales and is currently going through external validation, we are proud to report that early results indicate that AptameX™ Gen 2 Covid-19 rapid calibration shows
a strong performance against other forms of testing.

“The price versus performance, user friendliness, and the affordability of the test compares well against other categories of testing,” said Steven Goh, CEO of Achiko AG. “As the world considers Covid-19 as endemic, the shift is now to deliver the right test for key industries such as healthcare, manufacturing, tourism and leisure, key government and other applications.”

See the test performance here:

Achiko seeks to improve the lives of its customers through the use of innovative application technology.

Achiko held its Annual General Meeting on December 20 and we are pleased to announce that all resolutions were duly pass...
20/12/2022

Achiko held its Annual General Meeting on December 20 and we are pleased to announce that all resolutions were duly passed. The Board of Directors would like to thank all those who exercised their rights as shareholders in this way. Details can be found here:

Achiko seeks to improve the lives of its customers through the use of innovative application technology.

06/12/2022

Large gaps remain, momentum has stalled and inequality is widening

Address


Alerts

Be the first to know and let us send you an email when Achiko posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Achiko:

  • Want your practice to be the top-listed Clinic?

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram